Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vilin Bio MedNSE:VILINBIO +4.93%69 ROA % is 11.34% as of Mar. 2026, which is 1203% above its 10-year median of 0.87. GuruFocus rates NSE:VILINBIO with a GF Score™ of 69/100 and a GF Value™ of ₹75.10 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Vilin Bio Med ranks better than 65.24% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Vilin Bio Med's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹35.5 Mil.
Vilin Bio Med's average Total Assets over the quarter that ended in Mar. 2026 was ₹313.4 Mil. Therefore, Vilin Bio Med's annualized ROA % for the quarter that ended in Mar. 2026 was 11.34%.
The historical rank and industry rank for Vilin Bio Med's ROA % or its related term are showing as below:
NSE:VILINBIO'
s ROA % Range Over the Past 10 Years
Min: 0.24 Med: 0.87 Max: 7.97
Current: 5.67
During the past 7 years, Vilin Bio Med's highest ROA % was 7.97%. The lowest was 0.24%. And the median was 0.87%.
NSE:VILINBIO's ROA % is ranked better than 65.24% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 2.5
vs NSE:VILINBIO: 5.67
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Mar. 2026) net income data. The Revenue data used here is two times the semi-annual (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Vilin Bio Med ROA % Related Terms
Vilin Bio Med ROA % Historical Data
* Premium members only.
The historical data trend for Vilin Bio Med's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vilin Bio Med's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vilin Bio Med ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vilin Bio Med's ROA % distribution charts can be found below:
* The bar in red indicates where Vilin Bio Med's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Vilin Bio Med (NSE:VILINBIO) has a ROA % of 11.34% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Vilin Bio Med and its competitors. This is 1203% above median its historical median of 0.87. Over the past decade, Vilin Bio Med's ROA % has ranged from 0.24 to 7.97. According to the industry distribution chart, Vilin Bio Med ranks #350 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 34.8%.
Is Vilin Bio Med's ROA % too high?
Vilin Bio Med's current ROA % of 11.34% is 1203% above median its 10-year median of 0.87. Over the past 10 years, this metric has ranged from a low of 0.24 to a high of 7.97. The Drug Manufacturers industry median ROA % is 2.50. Vilin Bio Med's value of 11.34% is 353.6% above this industry median. Based on the distribution chart, Vilin Bio Med ranks #350 out of 1007 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Vilin Bio Med has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vilin Bio Med's ROA % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vilin Bio Med ranks #350 out of 1007 companies for ROA %. This puts Vilin Bio Med in the upper half of its industry. The industry median ROA % is 2.50. Vilin Bio Med's value of 11.34% is 353.6% above this benchmark. Historically, Vilin Bio Med's own ROA % has ranged from 0.24 to 7.97 over the past decade. While the company's 10-year median is 0.87 vs. the industry median of 2.50, Vilin Bio Med has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.50, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vilin Bio Med's current ROA % of 11.34% is 353.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Vilin Bio Med and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vilin Bio Med's current ROA % is 11.34%, which is 1203% above median its own 10-year median of 0.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vilin Bio Med stock overvalued right now?
Based on GuruFocus' analysis, Vilin Bio Med (NSE:VILINBIO) is currently considered Possible Value Trap. The stock's GF Value™ is ₹75.10, compared to a current price of ₹44.70 — trading 40.5% below its estimated fair value. The current ROA % is 11.34%, which is 1203% above median its 10-year median of 0.87 and 353.6% above the Drug Manufacturers industry median of 2.50. Vilin Bio Med's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Vilin Bio Med (NSE:VILINBIO), the current ROA % is 11.34% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vilin Bio Med (NSE:VILINBIO) Overvalued in 2026?
Based on GuruFocus' analysis, Vilin Bio Med stock appears to be undervalued.
The current stock price of ₹44.70 is trading 40.5% below its estimated GF Value™ of ₹75.10.
GuruFocus considers Vilin Bio Med to be Possible Value Trap.
Key valuation signals for NSE:VILINBIO:
ROA %: 11.34% (1203% above median its 10-year median of 0.87)
GF Value™: ₹75.10 vs. price of ₹44.70 (40.5% below fair value)
Industry Position: 353.6% above the Drug Manufacturers median (#350 of 1007)
No single metric tells the full story. See the NSE:VILINBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vilin Bio Med Ltd is engaged in the domestic business of manufacturing Pharmaceuticals products. It is manufacturing pharmaceutical formulations such as Oral Liquids, Dry syrups, Sachets, External Preparations, Beta and Non-Beta Lactam tablets, and Capsules and Nutritional Food supplements.
69GF Score
Get the complete analysis for NSE:VILINBIO
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:VILINBIO has been successfully added to your 
